Dr. Parsons is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-1992Fax+1 617-632-1930
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015- Johns Hopkins UniversityResidency, Internal Medicine, 2009 - 2012
Drexel University College of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2015 - 2026
MD State Medical License 2013 - 2015
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Start of enrollment: 2017 Oct 25
- STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.Diana Zhang, Shayesteh Jahanfar, Judy B Rabinowitz, Joshua Dower, Fei Song
Breast Cancer Research. 2025-03-12 - Clonal Hematopoiesis in Women With Breast Cancer.Christina Mayerhofer, Rachel A Freedman, Heather A Parsons, Ann H Partridge, Peter G Miller
Journal of Clinical Oncology. 2025-03-01 - Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer o...Ana C Garrido-Castro, Noah Graham, Lestat R Ali, Christina Herold, Jennifer Desrosiers
Journal for Immunotherapy of Cancer. 2025-02-25
Journal Articles
- Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate CancerHeather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
Press Mentions
Evolving Conversations in HER2+ Oligometastatic Breast Cancer ManagementSeptember 19th, 2024- STOP-HER2: Stopping Trastuzumab in HER2+ MBCFebruary 9th, 2023
- Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in AdvanceJune 10th, 2022
- Join now to see all
Grant Support
- Can a subset of patients with HER2+ metastatic breast cancer be cured?DANA-FARBER CANCER INST2021–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
